Compare Stocks → Move Your Money Before May 22 (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CARANASDAQ:SBTXNASDAQ:SPRYNASDAQ:VAXX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARACara Therapeutics$0.68-2.2%$0.83$0.50▼$4.67$37.41M0.7637,810 shs169,234 shsSBTXSilverback Therapeutics$8.09-2.1%$8.82$2.80▼$8.97$291.71M0.6337,931 shs534,709 shsSPRYARS Pharmaceuticals$8.35+3.2%$8.84$2.55▼$11.27$805.78M0.83609,969 shs520,296 shsVAXXVaxxinity$0.12-4.0%$0.64$0.11▼$3.10$14.78M2.39601,410 shs1.97 million shs(Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARACara Therapeutics+4.23%+1.45%-4.14%+21.42%-82.50%SBTXSilverback Therapeutics-2.06%-10.71%-19.10%+24.08%+24.46%SPRYARS Pharmaceuticals-2.06%-4.15%-19.10%+28.72%+25.23%VAXXVaxxinity-8.45%-73.88%-81.32%-82.08%-94.05%Move Your Money Before May 1 (Ad)Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? Click here to get the full story before May 1. MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCARACara Therapeutics3.6917 of 5 stars3.41.00.04.21.21.71.3SBTXSilverback TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASPRYARS Pharmaceuticals3.0687 of 5 stars3.51.00.00.03.25.00.6VAXXVaxxinity2.2129 of 5 stars3.51.00.00.02.23.30.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCARACara Therapeutics2.75Moderate Buy$9.751,324.81% UpsideSBTXSilverback TherapeuticsN/AN/AN/AN/ASPRYARS Pharmaceuticals3.00Buy$18.50121.56% UpsideVAXXVaxxinity3.00Buy$7.005,903.43% UpsideCurrent Analyst RatingsLatest VAXX, SPRY, SBTX, and CARA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/28/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/11/2024SPRYARS PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$19.003/6/2024CARACara TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.003/5/2024CARACara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/5/2024SPRYARS PharmaceuticalsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform3/5/2024SPRYARS PharmaceuticalsSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$6.00 ➝ $18.002/21/2024SPRYARS PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$19.002/20/2024SPRYARS PharmaceuticalsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCARACara Therapeutics$20.97M1.78N/AN/A$1.05 per share0.65SBTXSilverback TherapeuticsN/AN/AN/AN/A$7.41 per shareN/ASPRYARS Pharmaceuticals$30K26,859.17N/AN/A$2.40 per share3.48VAXXVaxxinity$70K211.13N/AN/A$0.11 per share1.06Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCARACara Therapeutics-$118.51M-$2.18N/AN/AN/A-565.21%-122.10%-89.64%5/20/2024 (Estimated)SBTXSilverback Therapeutics-$89.48M-$2.42N/A∞N/AN/A-29.62%-28.20%N/ASPRYARS Pharmaceuticals-$54.37M-$0.57N/AN/AN/AN/A-22.24%-21.50%5/20/2024 (Estimated)VAXXVaxxinity-$56.93M-$0.45N/AN/AN/AN/A-192.58%-88.04%5/14/2024 (Estimated)Latest VAXX, SPRY, SBTX, and CARA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2024Q4 2023VAXXVaxxinity-$0.13-$0.09+$0.04-$0.09N/AN/A3/21/2024Q4 2023SPRYARS Pharmaceuticals-$0.14-$0.07+$0.07-$0.07N/AN/A3/4/202412/31/2023CARACara Therapeutics-$0.57-$0.59-$0.02-$0.59$2.34 million$3.00 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCARACara TherapeuticsN/AN/AN/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/AN/ASPRYARS PharmaceuticalsN/AN/AN/AN/AN/AVAXXVaxxinityN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCARACara TherapeuticsN/A4.544.43SBTXSilverback TherapeuticsN/A67.8767.87SPRYARS PharmaceuticalsN/A96.9296.92VAXXVaxxinity0.991.891.89OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCARACara Therapeutics44.66%SBTXSilverback Therapeutics74.89%SPRYARS Pharmaceuticals68.16%VAXXVaxxinity82.95%Insider OwnershipCompanyInsider OwnershipCARACara Therapeutics4.20%SBTXSilverback Therapeutics34.40%SPRYARS Pharmaceuticals35.60%VAXXVaxxinity59.07%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCARACara Therapeutics5554.67 million52.37 millionOptionableSBTXSilverback Therapeutics8336.06 million23.65 millionNot OptionableSPRYARS Pharmaceuticals2496.50 million62.15 millionOptionableVAXXVaxxinity57126.75 million51.88 millionNot OptionableVAXX, SPRY, SBTX, and CARA HeadlinesSourceHeadlineWhy Is Vaxxinity (VAXX) Stock Down 58% Today?investorplace.com - April 22 at 8:40 AMVaxxinity Plans to Delist Shares From Nasdaqmarketwatch.com - April 19 at 7:30 PMVaxxinity Issues Shareholder Letterglobenewswire.com - April 19 at 6:53 PMVaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stockglobenewswire.com - April 19 at 4:27 PMVaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meetingglobenewswire.com - March 28 at 9:23 AMVAXX Stock Earnings: Vaxxinity Beats EPS for Q4 2023investorplace.com - March 27 at 11:03 PMVaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updatesglobenewswire.com - March 27 at 4:41 PMVaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD™ 2024globenewswire.com - March 7 at 10:32 AMVaxxinity’s Heart Health Innovation to Reduce LDL Cholesterol Levelsfinance.yahoo.com - February 15 at 2:41 PMVaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Publishedfinance.yahoo.com - February 15 at 9:40 AMVaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Publishedglobenewswire.com - February 15 at 8:00 AMVaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024finance.yahoo.com - February 13 at 8:20 AMVaxxinity, UF Join Forces Against Neurodegenerative Diseasesfinance.yahoo.com - January 30 at 2:16 PMVaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Floridafinance.yahoo.com - January 30 at 9:15 AMVaxxinity & UCF to Collaborate on Space Medicine Researchfinance.yahoo.com - January 19 at 3:05 PMVaxxinity Announces Collaboration on Space Medicine Research with University of Central Floridafinance.yahoo.com - January 18 at 8:33 AMVaxxinity to Present at the 2024 J.P. Morgan Healthcare Conferencefinance.yahoo.com - January 3 at 12:34 PMThe Zacks Analyst Blog Highlights Biogen, Prothena, AC Immune's and Vaxxinityfinance.yahoo.com - December 12 at 11:22 AMAlzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Othersmarkets.businessinsider.com - November 21 at 7:47 PMSeveral Alzheimer's vaccines enter clinical trials amid breakthrough treatments' successfoxnews.com - November 20 at 6:32 PMResearchers return to Alzheimer's vaccines, buoyed by recent drug successmsn.com - November 20 at 8:31 AMVaxxinity to Present at Upcoming November Medical and Investor Conferencesfinance.yahoo.com - November 13 at 7:50 PMVaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - November 8 at 9:19 AMPrivate companies invested in Vaxxinity, Inc. (NASDAQ:VAXX) copped the brunt of last week's US$41m market cap declinefinance.yahoo.com - October 10 at 4:04 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCara TherapeuticsNASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Silverback TherapeuticsNASDAQ:SBTXSilverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.ARS PharmaceuticalsNASDAQ:SPRYARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.VaxxinityNASDAQ:VAXXVaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and VXX-301, an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; VXX-401 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Merritt Island, Florida. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.